ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lumacaftor

Also written as “LUM/IVA”, “Lumacaftor” and “VX-809”.

Its studies are mostly in Cystic Fibrosis · Cognitive Dysfunction, led by 3 companies.

Drug pageLumacaftor: every studyAll 24 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Aug 15, 201623 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticalsits history only210 open or runningphase 4since Aug 15, 2016Mar 18, 2009none ahead
Qanatpharma11 open or runningphase 2since May 5, 2025May 5, 2025May 2027phase 2 · NCT07695090
Qanatpharma Canadaits history only10 open or runningphase 1since Jul 21, 2023Jul 21, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Qanatpharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 5, 2025First study: phase 2 study in Cognitive DysfunctionFirst studyNCT07695090 · 60 planned · Canada

Ahead

  1. May 2027Primary completion: phase 2 study in Cognitive DysfunctionNCT07695090

TargetBeta

CFTR →read by rule
“Cystic fibrosis transmembrane conductance regulator stabiliser”ChEMBL 37, by rule

Other programs on CFTR

ProgramCompanyFurthest phaseStudies
ivacaftorruleVertex Pharmaceuticalsphase 478
tezacaftorruleVertex Pharmaceuticalsphase 339

Studies

The one study Qanatpharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07695090Cognitive Dysfunction · Canada2RecruitingMay 202760

How it is read

Names in the registry

  • “LUM/IVA”, 8 entries
  • “Lumacaftor”, 5 entries
  • “VX-809”, 4 entries
  • “Lumacaftor Plus Ivacaftor Combination”, 3 entries
  • “Lumacaftor 200 MG”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.